NCT07450027Completed
LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis
Serum LRFN5 and OLFM4 Levels in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Cross-Sectional Case-Control Study
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 111 (actual)
- First submitted
- 27 Feb 2026
- Start date
- 1 Sept 2025
- Primary completion date
- 1 Apr 2026
- Lead sponsor
- Elazığ Mental Health and Diseases Hospital
- Diseases
- Schizophrenia
- NCT number
- NCT07450027
What you commit to
- Study type: Observational
- Participants enrolled: 111
- From 1 Sept 2025 to the primary completion date, 1 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- For Methamphetamine Use Disorder (MUD) Group:
- \*Inclusion Criteria:
- Diagnosis of MUD according to DSM-5-TR
- Medication-free for at least one month prior to admission
- Age ≥ 18 years and \<65 years
- Provided informed consent
- For Methamphetamine Use Disorder (MUD) Group:
- \*Exclusion Criteria:
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than MUD
- Alcohol use disorder
- For Methamphetamine-Induced Psychotic Disorder (MP) Group:
- \*Inclusion Criteria:
- Diagnosis of MP according to DSM-5-TR
- Medication-free for at least one month prior to admission
- Age ≥ 18 years and \<65 years
- Provided informed consent
- For Methamphetamine-Induced Psychotic Disorder (MP) Group:
- \*Exclusion Criteria:
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than MP
- Alcohol use disorder
- For Healthy Control Group:
- \*Inclusion Criteria:
- No psychiatric diagnosis
- No systemic or immunological illness
- Medication-free for at least one month
- Age ≥ 18 years and \<65 years
- Provided informed consent
- For Healthy Control Group:
- \*Exclusion Criteria:
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than schizophrenia
- Alcohol/drug/substance use
Age in the registry: 18 years to 49 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Elazığ Mental Health and Diseases Hospital Coordinator of this site? Confirm its status | Elâzığ | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.